For the quarter ending 2026-03-31, MD had -$169,461K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment losses | - | 0 | 0 | 0 |
| Loss on disposal of businesses | - | 0 | 0 | 0 |
| Net income | 29,572 | 33,683 | 71,708 | 59,997 |
| Depreciation and amortization | 6,119 | 5,631 | 5,551 | 10,645 |
| Net gain on investments in divested businesses | - | 0 | 20,906 | - |
| Amortization of premiums, discounts and issuance costs | 103 | 237 | 240 | 458 |
| Stock-based compensation expense | 4,661 | 5,345 | 5,150 | 7,550 |
| Deferred income taxes | 8,342 | 24,547 | 11,135 | 16,504 |
| Other | 670 | 1,176 | 1,885 | 1,501 |
| Accounts receivable | -4,864 | -1,457 | -7,870 | -21,231 |
| Prepaid expenses and other current assets | -34 | 2,136 | 988 | -204 |
| Other long-term assets | -4,744 | -4,826 | -7,371 | -9,601 |
| Accounts payable and accrued expenses | -181,467 | 67,165 | 51,118 | -89,951 |
| Payment of contingent consideration liability | - | - | 318 | - |
| Income taxes payable | 871 | -10,591 | 4,614 | 4,763 |
| Long-term professional liabilities | -1,112 | -1,252 | 760 | -8,166 |
| Other liabilities | -5,563 | -13,450 | -3,305 | -9,315 |
| Net cash used in operating activities - continuing operations | -129,502 | 114,604 | 138,115 | 22,020 |
| Net cash used in operating activities - discontinued operations | -345 | -502 | -830 | -2,316 |
| Net cash used in operating activities | -129,847 | 114,102 | 137,285 | 19,704 |
| Acquisition payments, net of cash acquired | 7,000 | 4,000 | 19,196 | 0 |
| Purchases of investments | 7,008 | 6,367 | 1,955 | 21,529 |
| Proceeds from maturities or sales of investments | 7,750 | 5,250 | 3,044 | 18,380 |
| Proceeds from investment in divested business | - | 0 | 30,000 | - |
| Purchases of property and equipment | 6,247 | 5,287 | 5,338 | 7,833 |
| Other | -526 | -122 | -49 | 3,636 |
| Net cash used in investing activities | -11,979 | -10,282 | 6,604 | -14,618 |
| Borrowings on line of credit | - | - | 0 | 0 |
| Payments on line of credit | - | - | 0 | 0 |
| Payments on term loan | -7,813 | - | 4,688 | 9,375 |
| Payments on finance lease obligations | -868 | - | 502 | 844 |
| Payment of contingent consideration liability | - | - | 3,182 | - |
| Proceeds from issuance of common stock | -1,994 | - | 700 | 1,838 |
| Repurchases of common stock | -1,194 | - | 20,867 | 1,778 |
| Other | 158 | - | -23 | -135 |
| Net cash used in financing activities | -27,635 | -68,638 | -28,562 | -10,294 |
| Net decrease in cash and cash equivalents | -169,461 | 35,182 | 115,327 | -5,208 |
| Cash and cash equivalents at beginning of period | 375,241 | 340,059 | 229,940 | - |
| Cash and cash equivalents at end of period | 205,780 | 375,241 | 340,059 | - |
Pediatrix Medical Group, Inc. (MD)
Pediatrix Medical Group, Inc. (MD)